Find, compare & contact
Alcuronium
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Alcuronium API 23214-96-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Alcuronium. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Alcuronium
- Synonyms:
- Alcuronum , Alloferine , Diallylnortoxiferine , Diallyltoxiferine , N,N'-diallyl-bis-nor-toxiferine , N,N'-Diallylnortoxiferinium
- Cas Number:
- 23214-96-2
- DrugBank number:
- DB13648
- Unique Ingredient Identifier:
- S8U3J5W06N
General Description:
Alcuronium, identified by CAS number 23214-96-2, is a notable compound with significant therapeutic applications. A non-depolarizing skeletal muscle relaxant similar to . It is used as an anesthesia adjuvant.
Classification:
Alcuronium belongs to the class of organic compounds known as strychnos alkaloids. These are alkaloids having a core structure based on the strychnan, stemmadenine (seco-curan), or the akuammicine (curan) skeleton, classified under the direct parent group Strychnos alkaloids. This compound is a part of the Organic compounds, falling under the Alkaloids and derivatives superclass, and categorized within the Strychnos alkaloids class, specifically within the None subclass.
Categories:
Alcuronium is categorized under the following therapeutic classes: Adjuvants, Anesthesia, Alkaloids, Amines, Anticholinergic Agents, Benzylisoquinolines, Central Nervous System Agents, Central Nervous System Depressants, Cholinergic Agents, Curare Alkaloids, Heterocyclic Compounds, Fused-Ring, Isoquinolines, Muscle Relaxants, Muscle Relaxants, Peripherally Acting Agents, Musculo-Skeletal System, Neuromuscular Agents, Neuromuscular Blocking Agents, Neuromuscular-Blocking Agents (Nondepolarizing), Neurotransmitter Agents, Nicotinic Antagonists, Onium Compounds, Peripheral Nervous System Agents, Quaternary Ammonium Compounds, Tetrahydroisoquinolines, Toxiferine. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Alcuronium is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
